Health Outcomes and Primary Adherence to Secondary Prevention Treatment after St-Elevation Myocardial Infarction: a Spanish Cohort Study
Por:
Padilla López A, Alós-Almiñana M and Peris JE
Publicada:
1 abr 2021
Ahead of Print:
1 jun 2020
Resumen:
This retrospective observational study aimed to establish the first prescription and its dispensation (primary adherence) in the first 30 days of the four pharmacotherapeutic classes recommended after a type 1 STEMI episode, determine the potential risk factors for lack of primary adherence, and evaluate the potential impact of primary adherence on cardiovascular outcomes. Of the 613 patients analyzed, 576 were included (64.7 +/- 13.8 years, 73.8% men) between January 2008 and December 2013. Primary adherence exceeded 90% in all groups. Complete primary adherence was higher in high-drug coverage patients and was lower in patients with cardiovascular or neuropsychiatric diseases. According to competing risk analysis, 1-year cardiovascular mortality was significantly lower in patients with complete primary adherence than in those without complete prescription or adherence, 1.8% versus 5.6% (HR = 0.286;p = 0.012). Complete primary adherence did not prevent a 1-year cardiovascular event, 5.6% versus 5.5% (p = 0.904).
Filiaciones:
:
Department of Pharmacy, Primary Care, Clinico-Malvarrosa Health Area, Valencia, Spain.
Department of Pharmacy, Primary Care, Gandia Health Area, Gandia, Valencia, Spain.
Alós-Almiñana M:
Department of Pharmacy, University Clinical Hospital, Valencia, Spain
Peris JE:
Department of Pharmacy and Pharmaceutical Technology, Faculty of Pharmacy, University of Valencia, Valencia, Spain
|